Another study shows that FOXO3 activation increases expression of TRAIL and cell death in response to doxorubicin in hepatocellular carcinoma (HCC), suggesting that FOXO3 is required for doxorubicin sensitivity. Here, FOXO3 is linked to hepatocellular carcinoma.